IDH1 and glioblastoma: Transduced U87MG and T98G glioblastoma cells, bearing the wild-type or mutated form of IDH1 were treated with increasing concentrations of the BH-3 mimetic ABT263, a known inhibitor of both Bcl-xL and Bcl-2.